Effectiveness of Weight Loss Methods on Lifespan for Metabolic Syndrome
NCT06410352 on ClinicalTrials.gov · last registry update 2025-11-26
An unusually large phase 4: 220 participants, more than double the 72 typical for the stage. The sponsor logged completion for 30 September 2025. Primary outcome, as filed: Weight. semaglutide is approved in the US, but not for metabolic syndrome — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- RECRUITING
- Phase
- P4
- Drug
- semaglutideWegovy, Ozempic, Rybelsus
- Sponsor
- University Medical Center, Kazakhstan
- Sponsor type
- Other
- Enrollment
- 220
- Started
- 2024-03-01
- Primary completion
- 2025-09-30 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Weight
Conditions studied
Metabolic Syndrome
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.